TY - JOUR
T1 - International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia
AU - GLIMP Investigators
AU - Aliberti, Stefano
AU - Cook, Grayden S.
AU - Babu, Bettina L.
AU - Reyes, Luis F.
AU - Rodriguez, Alejandro H.
AU - Sanz, Francisco
AU - Soni, Nilam J.
AU - Anzueto, Antonio
AU - Faverio, Paola
AU - Sadud, Ricardo Franco
AU - Muhammad, Irfan
AU - Prat, Cristina
AU - Vendrell, Ester
AU - Neves, Joao
AU - Kaimakamis, Evangelos
AU - Feneley, Andrew
AU - Swarnakar, Rajesh
AU - Franzetti, Fabio
AU - Carugati, Manuela
AU - Morosi, Manuela
AU - Monge, Elisa
AU - Restrepo, Marcos I.
AU - Aruj, Patricia Karina
AU - Attorri, Silvia
AU - Barimboim, Enrique
AU - Caeiro, Juan Pablo
AU - Garzón, María I.
AU - Cambursano, Victor Hugo
AU - Ceccato, Adrian
AU - Chertcoff, Julio
AU - Lascar, Florencia
AU - Di Tulio, Fernando
AU - Díaz, Ariel Cordon
AU - de Vedia, Lautaro
AU - Ganaha, Maria Cristina
AU - Lambert, Sandra
AU - Lopardo, Gustavo
AU - Luna, Carlos M.
AU - Malberti, Alessio Gerardo
AU - Morcillo, Nora
AU - Tartara, Silvina
AU - Pensotti, Claudia
AU - Pereyra, Betiana
AU - Scapellato, Pablo Gustavo
AU - Stagnaro, Juan Pablo
AU - Shah, Sonali
AU - Lötsch, Felix
AU - Thalhammer, Florian
AU - Levine, Stephanie M.
AU - Angel, Luis F.
N1 - Publisher Copyright:
© 2019
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility data. Multivariate logistic regressions were used to identify risk factors independently associated with DRSP-CAP. Results: 3,193 subjects were included in the study. The global prevalence of DRSP-CAP was 1.3% and continental prevalence rates were 7.0% in Africa, 1.2% in Asia, and 1.0% in South America, Europe, and North America, respectively. Macrolide resistance was most frequently identified in subjects with DRSP-CAP (0.6%) followed by penicillin resistance (0.5%). Subjects in Africa were more likely to have DRSP-CAP (OR: 7.6; 95%CI: 3.34-15.35, p<0.001) when compared to centres representing other continents. Conclusions: This multinational point-prevalence study found a low global prevalence of DRSP-CAP that may impact guideline development and antimicrobial policies.
AB - Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility data. Multivariate logistic regressions were used to identify risk factors independently associated with DRSP-CAP. Results: 3,193 subjects were included in the study. The global prevalence of DRSP-CAP was 1.3% and continental prevalence rates were 7.0% in Africa, 1.2% in Asia, and 1.0% in South America, Europe, and North America, respectively. Macrolide resistance was most frequently identified in subjects with DRSP-CAP (0.6%) followed by penicillin resistance (0.5%). Subjects in Africa were more likely to have DRSP-CAP (OR: 7.6; 95%CI: 3.34-15.35, p<0.001) when compared to centres representing other continents. Conclusions: This multinational point-prevalence study found a low global prevalence of DRSP-CAP that may impact guideline development and antimicrobial policies.
KW - Global burden of disease
KW - Microbial drug resistant
KW - Pneumococcal infection
KW - Pneumonia
UR - http://www.scopus.com/inward/record.url?scp=85069669834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069669834&partnerID=8YFLogxK
U2 - 10.1016/j.jinf.2019.07.004
DO - 10.1016/j.jinf.2019.07.004
M3 - Article
C2 - 31299410
AN - SCOPUS:85069669834
SN - 0163-4453
VL - 79
SP - 300
EP - 311
JO - Journal of Infection
JF - Journal of Infection
IS - 4
ER -